ROADMAP
Alzheimer’s disease is on the rise in our ageing population, and new, effective treatments are urgently needed. Currently, the safety and benefits to patients of potential treatments are assessed in strictly-controlled clinical trials. However, clinical trials do not provide information on the health benefits for patients in their daily lives in the ‘real world’. The ROADMAP project aims to deliver a series of methods and tools that will allow the scalable, transferable integration of data on patient outcomes in the real world. The tools will be developed and tested through pilot projects and will lay the foundations for a Europe-wide platform on real world evidence in Alzheimer’s disease. The project will also deliver tools for patient engagement and address the ethical, legal and social implications of adopting a real world evidence approach to Alzheimer’s disease. The project is part of IMI’s Big Data for Better Outcomes programme, which aims to facilitate the use of diverse data sources to deliver results that reflect health outcomes of treatments that are meaningful for patients, clinicians, regulators, researchers, healthcare decision-makers, and others.
The Chancellor Masters And Scholars Of The University Of Oxford
National Institute For Health And Care Excellence
Erasmus Universitair Medisch Centrum Rotterdam
Universiteit Maastricht
ynapse Research Management Partners Sl
Fundacio Institut Universitari Pera La Recerca A L'Atencio Primaria De Salut Jordi Gol I Gurina
Kobenhavns Universitet
Alzheimer Europe
The University Of Edinburgh Goeteborgs Universitet
Aarhus Universitet
London School Of Economics And Political Science
Agentschap College Ter Beoordeling Van Geneesmiddelen
Ixico Technologies Limited
Rijksuniversiteit Groningen
Novartis Pharma Ag
Eli Lilly And Company Limited
Biogen Idec Limited
F. Hoffmann-La Roche Ag
Janssen Pharmaceutica Nv
GE Healthcare Limited
AC Immune Sa
Takeda Development Centre Europe Ltd
H. Lundbeck As
Academisch Ziekenhuis Leiden
Chu Hopitaux De Bordeaux